TrialCancer science2022

Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.

Kensei Yamaguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.